GBLX: AI 评分 49/100 — AI 分析 (4月 2026)

GB Sciences, Inc. is a biotechnology company focused on the research and development of plant-based medicines. They target conditions like Parkinson's disease and chronic pain with cannabinoid-inspired therapies.

Key Facts: AI Score: 49/100 Sector: Healthcare

公司概况

概要：

GB Sciences, Inc., operating in the biotechnology sector, researches and develops plant-based medicines, including cannabinoid-inspired therapies, targeting conditions like Parkinson's disease and neuropathic pain. With pre-clinical programs and a focus on complex therapeutic mixtures, the company aims to serve the prescription drug market in North America and Europe.

GBLX是做什么的？

GB Sciences, Inc., founded in 2001 and based in Las Vegas, Nevada, is a biotechnology company dedicated to the research and development of plant-based medicines. Originally incorporated as Growblox Sciences, Inc., the company rebranded in October 2016 to reflect its evolving focus. GB Sciences develops cannabinoid-inspired medicines and complex therapeutic mixtures intended for the prescription drug market. Their research spans a range of conditions, including Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular ailments. The company's intellectual property portfolio covers these therapeutic areas, with programs currently in the pre-clinical animal stage. GB Sciences operates in both North America and Europe, seeking to bring innovative, plant-based solutions to address unmet medical needs. Their strategy involves rigorous scientific investigation and the development of proprietary formulations to create effective and safe therapies. With a small team of 2 employees, the company outsources many functions. GB Sciences is positioned to capitalize on the growing acceptance of plant-based medicines and the increasing demand for novel therapeutic options.

GBLX的投资论点是什么？

GB Sciences, Inc. presents a high-risk, high-reward investment profile characteristic of early-stage biotechnology firms. The company's focus on plant-based medicines, particularly cannabinoid-inspired therapies, aligns with growing market interest in alternative treatments. However, with a market capitalization of $0.00B and negative profitability (P/E of -0.28 and a profit margin of -299.6%), the company's financial stability is a significant concern. The company's gross margin is 100.0%. The success of GB Sciences hinges on advancing its pre-clinical programs to clinical trials and ultimately securing regulatory approvals. The high beta of 9.86 indicates extreme volatility. Investors should carefully consider the risks associated with OTC-traded companies and the uncertainty inherent in pharmaceutical development.

GBLX在哪个行业运营？

GB Sciences operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The market for plant-based medicines is expanding, driven by increasing consumer interest in natural and alternative therapies. However, the industry is also subject to stringent regulations and lengthy approval processes. GB Sciences competes with other biotechnology companies, including ACUS, BIOAF, EHOS, GSTC and HTDS, some of which have greater resources and more advanced clinical programs. Success in this industry requires strong scientific expertise, effective regulatory strategies, and substantial capital investment.

Biotechnology

Healthcare

GBLX有哪些增长机遇？

Advancement of Parkinson's Disease Program: GB Sciences has a pre-clinical program targeting Parkinson's disease. The Parkinson's disease treatment market is projected to reach $5.6 billion by 2027. Successfully transitioning this program to clinical trials and demonstrating efficacy could unlock significant value for the company. The timeline for this catalyst depends on securing funding and completing pre-clinical studies, potentially leading to clinical trials within the next 2-3 years.
Development of Neuropathic Pain Therapies: The company is developing plant-based medicines for neuropathic pain, a market estimated at $8.3 billion globally. Achieving positive results in pre-clinical studies and advancing to clinical trials could position GB Sciences as a player in this large and growing market. This growth opportunity is contingent on successful pre-clinical data, which could lead to clinical trial initiation within 2-3 years.
Expansion into Cardiovascular Therapeutics: GB Sciences has a cardiovascular therapeutic program in the pre-clinical stage. The global cardiovascular disease market is substantial, offering significant potential for new therapies. Progressing this program through pre-clinical and clinical stages could diversify the company's pipeline and create new revenue streams. This is a longer-term opportunity, with potential clinical trials 3-5 years out.
Commercialization of COVID-Related Cytokine Release Syndrome Treatment: GB Sciences is researching treatments for COVID-related cytokine release syndrome. While the urgency of the COVID-19 pandemic has decreased, there remains a need for effective treatments for complications arising from the virus. Successful development and commercialization of such a treatment could provide a near-term revenue opportunity. This opportunity depends on ongoing research and potential regulatory pathways, possibly yielding results within the next 1-2 years.
Strategic Partnerships and Licensing Agreements: GB Sciences can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Licensing agreements can provide upfront payments, milestone payments, and royalties, generating revenue and validating the company's technology. The timing and success of such partnerships are uncertain but represent a potential growth driver in the near to medium term.

Market Cap of $0.00B reflects the company's small size and early stage of development.
P/E Ratio of -0.28 indicates the company is not currently profitable.
Profit Margin of -299.6% demonstrates significant losses relative to revenue.
Gross Margin of 100.0% suggests high potential profitability if research and development costs can be managed effectively.
Beta of 9.86 indicates the stock is significantly more volatile than the market average.

GBLX提供哪些产品和服务？

Researches and develops plant-based medicines.
Focuses on cannabinoid-inspired therapies.
Targets conditions like Parkinson's disease, neuropathic pain, and chronic pain.
Develops complex therapeutic mixtures for the prescription drug market.
Conducts pre-clinical animal studies to evaluate drug candidates.
Seeks to create innovative and effective treatments for unmet medical needs.
Operates in North America and Europe.

GBLX如何赚钱？

Develops proprietary plant-based medicine formulations.
Out-licenses or partners with larger pharmaceutical companies for clinical trials and commercialization.
Generates revenue through licensing fees, milestone payments, and royalties.

Pharmaceutical companies seeking novel drug candidates.
Patients with conditions like Parkinson's disease, neuropathic pain, and chronic pain.
Healthcare providers prescribing plant-based medicines.

Intellectual property portfolio covering various therapeutic areas.
Expertise in developing cannabinoid-inspired medicines.
Focus on plant-based therapies, aligning with growing market trends.
Proprietary formulations and drug delivery systems.

什么因素可能推动GBLX股价上涨？

Upcoming: Announcement of results from pre-clinical studies for Parkinson's disease program (timeline: next 6-12 months).
Upcoming: Initiation of clinical trials for neuropathic pain therapy (timeline: next 12-18 months, contingent on funding).
Ongoing: Pursuit of strategic partnerships with larger pharmaceutical companies.
Ongoing: Expansion of intellectual property portfolio through new patent filings.
Ongoing: Research and development efforts to advance drug candidates through the pipeline.

GBLX的主要风险是什么？

Potential: Failure to secure funding for clinical trials.
Potential: Negative results from clinical trials.
Potential: Regulatory delays or rejection of drug candidates.
Ongoing: Competition from larger biotechnology companies with greater resources.
Ongoing: Limited financial resources and dependence on external funding.

GBLX的核心优势是什么？

Focus on plant-based medicines.
Intellectual property portfolio.
Pre-clinical programs targeting unmet medical needs.
Expertise in cannabinoid-inspired therapies.

GBLX的劣势是什么？

Limited financial resources.
Small team size.
Early stage of development.
Dependence on external funding and partnerships.

GBLX有哪些机遇？

Growing market for plant-based medicines.
Strategic partnerships with larger pharmaceutical companies.
Advancement of pre-clinical programs to clinical trials.
Expansion into new therapeutic areas.

GBLX面临哪些威胁？

Regulatory hurdles and approval processes.
Competition from larger biotechnology companies.
Uncertainty in clinical trial outcomes.
Fluctuations in market demand for plant-based therapies.

GBLX的竞争对手是谁？

Agenus Inc. — Focuses on immuno-oncology. — (ACUS)
BioAffinity Technologies, Inc. — Develops diagnostics and therapeutics for cancer. — (BIOAF)
Ehouse Global Inc. — Operates in the real estate sector. — (EHOS)
Gastech Solutions, Inc. — Provides gas technology solutions. — (GSTC)
Harte Hanks, Inc. — Offers customer experience solutions. — (HTDS)

Key Metrics

MoonshotScore: 49/100

Company Profile

CEO: Andrea Small-Howard
Headquarters: Las Vegas, US
Employees: 2
Founded: 2008

AI Insight

AI analysis pending for GBLX

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does GB Sciences, Inc. do?

GB Sciences, Inc. is a biotechnology company focused on the research and development of plant-based medicines, particularly cannabinoid-inspired therapies. The company aims to create complex therapeutic mixtures for the prescription drug market, targeting conditions such as Parkinson's disease, neuropathic pain, chronic pain, and COVID-related cytokine release syndrome. Their work is currently in the pre-clinical stage, involving animal studies to assess the safety and efficacy of their drug candidates. The company operates in North America and Europe, seeking to address unmet medical needs through innovative, plant-based solutions.

What do analysts say about GBLX stock?

As of March 17, 2026, there is no readily available analyst coverage or consensus on GB Sciences, Inc. (GBLX) due to its OTC listing and small market capitalization. Investors should conduct their own thorough due diligence and consider the risks associated with investing in OTC-traded companies. Key valuation metrics, such as price-to-earnings ratio and revenue growth, may not be meaningful due to the company's current financial performance. Growth considerations depend on the successful advancement of pre-clinical programs and securing regulatory approvals.

What are the main risks for GBLX?

The main risks for GB Sciences, Inc. include its limited financial resources, dependence on external funding, and the inherent uncertainties of drug development. The company's pre-clinical programs face the risk of failure in clinical trials or regulatory rejection. Competition from larger biotechnology companies with greater resources poses a significant challenge. As an OTC-traded company, GBLX is subject to lower levels of regulatory oversight and greater price volatility. Investors should carefully consider these risks before investing in GBLX.